ClinicalTrials.gg
CompletedNCT04752241IMAPSEXUpdated Jul 24, 2024

Preservation of Inferior Mesenteric Artery Could Improve Sexual Function After Laparoscopic Colorectal Resection for Diverticular Disease

An interventional study of Inferior Mesenteric Artery Preservation and Inferior Mesenteric Artery Ligation in Sexual Function Disturbances, sponsored by University of Roma La Sapienza. Completed at 1 site in Italy. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by University of Roma La Sapienza · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 9 years 1 month after the study started (first participant enrolled Jan 2012, registered Feb 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

This study aims to evaluate whether IMA sparing may represent an advantage in terms of reduced incidence and severity of sexual dysfunctions after colorectal resections for diverticular disease (DD).

Read the detailed description

Enrolled patients were randomly divided into 2 treatment groups. In the first group (IMAP) the IMA was preserved sectioning the sigmoid arteries near colonic wall while, in the second group (IMAS) the IMA was sectioned immediately below the origin of the left colic artery. Incidence and severity of sexual dysfunction and QoL were assessed by four validated questionnaire administered 6,12 months and 5 and 8 years after surgery.

02

Conditions studied

  • Sexual Function Disturbances

Keywords

  • Sexual function
  • Colonic diverticular disease
  • Inferior mesenteric artery-preserving
  • Neosigmoid Denervation
  • Postoperative sexual dysfunction
03

In context

Sexual Dysfunctions, Psychological

138 studies on the registry are indexed under Sexual Dysfunctions, Psychological; 10 are open to participants now.

This study's enrollment of 300 is above the median of 100 across 114 interventional studies indexed under Sexual Dysfunctions, Psychological.

Browse Sexual Dysfunctions, Psychological studies →

Lead sponsor

University of Roma La Sapienza is the lead sponsor of 398 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diverticular disease
  • Diverticulitis
  • under 35 Kg/mq
  • from I to III
  • Standardized sigmoid, left colon or rectal resection

Exclusion criteria

Exclusion Criteria:

  • complicated diverticulitis (Hinchey III-IV)
  • previous abdominal surgery or prostatic and/or gynecological resections
  • adverse local condition or the need of multiorgan resection or stoma creation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    IMAP

    Inferior Mesenteric Artery Preservation Performing left hemicolectomy and anterior rectal resection the IMA was preserved ligating close to the colonic wall the sigmoids arteries.

    Procedure: Inferior Mesenteric Artery Preservation

  • Active comparator
    IMAS

    Inferior Mesenteric Artery Ligation Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery

    Procedure: Inferior Mesenteric Artery Ligation

Interventions

  • ProcedureInferior Mesenteric Artery Preservation

    Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.

  • ProcedureInferior Mesenteric Artery Ligation

    Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery

06

What researchers measure

Primary outcomes

  1. Sexual disfunction 1

    Presence of sexual disfunction ( defined through the evaluation of sexual desire ,arousal, lubrication , orgasmic function, overall satisfaction, pain, intercourse satisfaction , erectile function)

    Time frame: 12 months after surgery

  2. Sexual disfunction 2

    Presence of sexual disfunction ( defined through the evaluation of sexual desire ,arousal, lubrication , orgasmic function, overall satisfaction, pain, intercourse satisfaction , erectile function)

    Time frame: 6 years after surgery

Secondary outcomes

  1. Sexual Function Male 1

    assess the patients' sexual disorders with International Index of Erectile Function (IIEF) 15-items test

    Time frame: 12 month after surgery

  2. Sexual Function Male 2

    assess the patients' sexual disorders with International Index of Erectile Function (IIEF) 15-items test

    Time frame: 6 years after surgery

  3. Sexual Function Female 1

    assess the patients' sexual disorders withFemale Sexual Function Index (FSFI) a 19-item test (score below 26.55 indicates the presence of sexual dysfunctions)

    Time frame: 12 months after surgery

  4. Sexual Function Female 2

    assess the patient's sexual disorders with Female Sexual Function Index (FSFI) 19-item test (score below 26.55 indicates the presence of sexual dysfunctions)

    Time frame: 6 years after surgery

  5. Quality of Life 1

    The impact of sexual disorders in QoL was evaluated using EORTC QLQ-30 ( European organisation for research and treatment of cancer- quality of life questionnaire)

    Time frame: 12 months after surgery

  6. Quality of Life 2

    The impact of sexual disorders in QoL was evaluated using EORTC QLQ-30( European organisation for research and treatment of cancer- quality of life questionnaire)

    Time frame: 6 years after surgery

  7. Quality of life SF-36 1

    The impact of sexual disorders in QoL was evaluated using SF-36 score (Short Form Health Survey 36)

    Time frame: 12 months after surgery

  8. Quality of life SF-36 2

    The impact of sexual disorders in QoL was evaluated using SF- 36 score ( Short Form Health Survey 36 )

    Time frame: 6 years after surgery

07

Study locations

1 site
  • Azienda Ospedaliera Sant'Andrea
    Rome, 00188, Italy
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2012 to primary completion in Jan 2018, 72 months.

Of 30 non-industry interventional studies with no phase under Sexual Dysfunctions, Psychological, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 24. This study's 72 months is above that.

Counting every sponsor, half of 30 studies reached it within 21 months; a quarter within 6 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 8, 2021
First posted
Feb 12, 2021
StartActual
Jan 1, 2012
Primary completionActual
Jan 1, 2018
CompletionActual
Jan 1, 2024
Last update
Jul 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04752241
Responsible party
Francesco Saverio Mari, MD, PhD, FACS (Researcher, University of Roma La Sapienza) — Principal investigator
First posted
Feb 12, 2021
Start date
Jan 1, 2012
Primary completion
Jan 1, 2018
Completion
Jan 1, 2024
Last update
Jul 24, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion